V.T. CHUBARYAN¹, E.I. MITCHENKO¹, I.A. POLOZYUKOV², D.S. DUDNICHENKO²

¹Rostov State Medical University, 29 Nakhichevanskiy alley, Rostov-on-Don, Russian Federation, 344022

²Specialized tuberculosis hospital, 24 Orskaya Str., Rostov-on-Don, Russian Federation, 344065

Chubaryan V.T. ― D. Med. Sc., Pofessor, Head of the Department of Phthisiology and Pulmonology, tel. (863) 223-36-04, e-mail: [email protected]

Mitchenko E.I. ― assistant of the Department of Phthisiology and Pulmonology, tel. +8-904-500-49-41, e-mail: [email protected]

Polozyukov I.A. ― Head of Surgical Department, tel. +7-918-554-58-61, e-mail: [email protected]

Dudnichenko D.S. ― thoracic surgeon, tel. +7-905-455-12-43, e-mail: [email protected]

Krotov Yu.P. ― thoracic surgeon, Deputy Chief Physician, tel. +7-904-340-22-82, e-mail: [email protected]

The article presents the results of a comparative study of the clinical assessment of reparant, cytoprotector and immunocorrector of sodium deoxyribonucleate (Derinat) in the postoperative period of surgical treatment of patients with pulmonary tuberculosis. 37 patients of the main group received Derinat in addition to standard therapy in the postoperative period ― 15 mg/ml intramuscular injection with 5 ml of solution, 5 injections per course. In the comparison group were observed 42 patients who did not receive Derinat. Clinical and laboratory parameters of patients in the postoperative period, the incidence of postoperative complications, relapse and recurrence of the disease in a prospective observation for 6-12 months were estimated. The inclusion of Derinat, solution for intramuscular injection of 15 mg/ml, in the treatment plan helped to reduce the number of complications in the early and deferred postoperative period, shorten the duration of hospitalization, step up the recovery of protein-synthetic function and reactivity of the organism, LII, parameters of hemo- and leukogram.

Key words: pulmonary tuberculosis, treatment, sodium deoxyribonucleate, Derinat, treatment efficacy.